Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities-Reference-Cited by-同舟云学术

Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities

Published:2017-02 Issue:1 Volume:3 Page:36-49
ISSN:2198-641X
Container-title:Current Pharmacology Reports
language:en
Short-container-title:Curr Pharmacol Rep

Author:

Fowler Stephen,Morcos Peter N.,Cleary Yumi,Martin-Facklam Meret,Parrott Neil,Gertz Michael,Yu Li

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,Genetics,Biochemistry

Link

http://link.springer.com/content/pdf/10.1007/s40495-017-0082-5.pdf

Reference102 articles.

1. Jamei M. Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance. Curr Pharmacol Rep. 2016;2:161–9. doi: 10.1007/s40495-016-0059-9 .

2. Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review. Drug Metab Dispos. 2014;42(12):1991–2001. doi: 10.1124/dmd.114.060392 .

3. Yu J, Ritchie TK, Zhou Z, Ragueneau-Majlessi I. Key findings from preclinical and clinical drug interaction studies presented in new drug and biological license applications approved by the Food and Drug Administration in 2014. Drug Metab Dispos. 2016;44(1):83–101. doi: 10.1124/dmd.115.066720 .

4. Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos. 2015;43(11):1823–37. doi: 10.1124/dmd.115.065920 .

5. •• Yu J, Zhou Z, Owens KH, Ritchie TK, Ragueneau-Majlessi I. What can be learned from recent new drug applications? A systematic review of drug interaction data for drugs approved by the US FDA in 2015. Drug Metab Dispos. 2017;45(1):86–108. doi: 10.1124/dmd.116.073411 . Highly informative overview of NDA information from 2015, covering many data which are not published as journal articles.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic;Drug Metabolism Reviews;2024-07-26

2. Recent Progress on Physiologically Based Pharmacokinetic (PBPK) Model: A Review Based on Bibliometrics;Toxics;2024-06-14

3. Computer simulations in pharmacokinetics;Physico-Chemical Aspects of Dosage Forms and Biopharmaceutics;2024

4. Novel Opioids in the Setting of Acute Postoperative Pain: A Narrative Review;Pharmaceuticals;2023-12-25

5. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes;European Journal of Pharmaceutical Sciences;2023-08